Postmortem assessment showed that treatment was able to prevent all major phenotypic features of AT-1 sTg mice, namely loss of body fat (Fig. 4c), loss of bone mineral density (Fig. 4d), splenomegaly (Fig. 4e, f), lymphadenopathy (Fig. 4g, h), and tissue inflammation (Fig. 4i, j). The gene discussed is SLC33A1; the disease is Lymphadenopathy.